Urol. praxi. 2019;20(4):157-160 | DOI: 10.36290/uro.2019.069

BCG – history, method principe, indication, effectivity, dosage

MUDr. Petr Hušek, FEBU, MUDr. Jaroslav Pacovský, Ph.D., prof. MUDr. Miloš Broďák, Ph.D.
Urologická klinika LF UK a FN Hradec Králové

Bacillus Calmette –Guerine intravesical therapy has become a standard treatment of high grade non-muscle invasive blader cancer
(Ta, T1) and cancer in situ (CIS) in clinical praktice with acceptable results. A lot of questions are still unclear. Goal of an article is
the summary BGG treatment and description of interesting historical evolution.

Keywords: BCG, urothelial cancer

Published: October 10, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hušek P, Pacovský J, Broďák M. BCG – history, method principe, indication, effectivity, dosage. Urol. praxi. 2019;20(4):157-160. doi: 10.36290/uro.2019.069.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Svobodová J. Vakcinační kmen Mycobacterium bovis BCG a očkování proti tuberkulóze. Zprávy Centra Epidemiologie a Mikrobiologie (SZÚ, Praha): 2014; 23(5).
    2. Behr MA, Small PM. A history and molecular phylogeny of BCG strains. Vaccine: 1999; 17: 915-922. Go to original source... Go to PubMed...
    3. Sylvester RJ, van der Meijden AP, Lamm DL, et al. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol, 2002; 168: 1964. Go to original source... Go to PubMed...
    4. Pearl R. Cancer and tuberculosis.Am J Hygiene. 1929; 9: 97-159. Go to original source...
    5. Zbar B, Bernstein ID, Bartlett GL, Hanna MG, Jr, Rapp HJ. Immunotherapy of cancer: regression of intradermal tumours and prevention of growth of lymph node metastases after intralessional injection of living Mycobacterium bovis. J Natl Cancer Inst. 1972; 49: 119-130.
    6. Coe JE, Feldman JD. Extracutaneous delayed hypersensitivity, particularly in quinea pig bladder. Immunolog 1966; 10: 127-136.
    7. Bloomberg SD, Brosman SA, Hausman MS, Cohen A, Battenberg JD. The effects of BCG on the dog bladder. Invest Urol. 1975; 12(6): 423-427. Go to PubMed...
    8. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumor. J Urol. 1976; 116(2): 180-183. Go to original source... Go to PubMed...
    9. Lamm DL, Thor DE, Harris CS, Reyna JA, Stogill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol. 1980; 124(1): 38-40. Go to original source...
    10. Lamm DL. Carcinoma in situ. Urol Clin North Am 1992; 19(3): 499-508. Go to original source... Go to PubMed...
    11. Drake T, Hicks J. BCG in bladder cancer: The morales of the story. Eur Urol 2014; Suppl: 13. Go to original source...
    12. Herr HW, Morales A. History of Bacillus Calmette-Guerin and Bladder Cancer: An Immunotherapy Succes Story. J Juro: 2007; 08: 122.
    13. Kavoussi R, Brown JE, Ritchey JK, et al. Fobronectin-mediated Calmette-Guerin bacillus attachment to bladder mucosa. Requirement for the expression of an antitumor response.J Clin Invest 1990; 85(1): 62-67. Go to original source...
    14. Luo Y, Chen X, O'Donnel MA. Role of Th1 a Th2 cytokines in BCG-induced IFN production: cytokine promotion and simulation of BCG effect. Cytokine 2003; 21(1): 17-26. Go to original source... Go to PubMed...
    15. Matoušková M. Imunoterapie uroteliálního karcinomu močového měchýře-od BCG vakcíny k cílené imunoterapii. Klin Onkol 2015; 28(Suppl 4): 4595-4602. Go to original source...
    16. Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala H. An individual patient data meta-analysis of the long-term outcomes of ramdomised studies comparing intravecical mitomycin C versus bacillus Calmette-Guérin fornnon-muscle-invasive bladder cancer. Eur Urol 2009; 56(2): 247-256. Go to original source... Go to PubMed...
    17. Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006; 67(6): 1216-1223. Go to original source... Go to PubMed...
    18. Shelley MD, Wilt TJ, Court J, Coles J, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour reccurence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004; 93(4): 485-490. Go to original source... Go to PubMed...
    19. Böhle A, Jocham D, Bock RP. Intravecical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on reccurence and toxicity. J Urol 2003; 169(1): 90-95. Go to original source... Go to PubMed...
    20. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized trials. J Urol 2002; 168: 1964-1970. Go to original source... Go to PubMed...
    21. Zlotta AR, van Vooren, JP, Huygen K, Drowart A, Decock M, Pirson M. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000; 37(4): 470-477. Go to original source... Go to PubMed...
    22. Oddens J, Brausi M, Sylvester R, Bono A, van de Beek, et al. Final result of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate ang high risk T1, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol, 2013; 63: 462. Go to original source... Go to PubMed...
    23. Martinez-Pineiro L, Portillo JA, Ferrnandez JM, Zabala JA, Cadierno I, Moyano JL, et al. Maintenance Therapy with 3-monthly Bacillus Calmette-Guerin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. Eur Urol, 2015; 68: 256. Go to original source... Go to PubMed...
    24. Sylvester, et al. Prediction Recurrence and Progresion in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Table: A Combined Analysis of 2596 Patients from Seven OERTC Trials: Eur. Urol 2006; 49: 466-477. Go to original source... Go to PubMed...
    25. Husek P, Pacovsky J, Chmelarova M, Podhola M, Brodak M. Methylation status as a predictor of intravesical Bacillus Calmette-Guérin (BCG) immunotherapy response of high grade non-muscle invasive bladder tumor. Biomed Pap Med Fac Univ Palacsky Olomouc Czech Reub. 2017 Jun; 161(2): 2102016. Go to original source...
    26. Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010; 57(1): 60-70. Go to original source... Go to PubMed...
    27. Witjes JA, Paulo J, Soloway M, Lamm D, Kamat AM, Brausi M. Clinical practice recommedations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl 2008 Oct; 7(10): 667-676. Go to original source...
    28. Herr WH, et al. BCG - refractory vs. BCG - relapsing non-muscle invasive badder cancer: a prospective kohort outcomes study. Urol Oncol. 2015; 33: 108. Go to original source... Go to PubMed...
    29. Takenaka A, et al. Clinical outcomes of bacillus Calmette-Querin instillation therapy for carcinoma in situ of urinary bladder. Int J Urol. 2008; 12: 309. Go to original source... Go to PubMed...
    30. Kaasinen E, et al. Alternating mitomycin C and BCG instillations versus BCG alone treatment of carcinoma in situ of the urinary bladder: a nordis study. Eur Urol. 2003; 43: 637. Go to original source... Go to PubMed...
    31. Solsona E, et al. Extravesical involment in patiens with bladder carcinoma in situ: biological and therapy implication. J Urol. 1996; 155: 895. Go to original source... Go to PubMed...
    32. Daniels MJ, Barry E, Schoenberg M, Lamm DL, Kates M. Contemporary oncologic outcomes of second induction course BCG in patient with nonmuscle invasive bladder cancer. Urol Oncol 2019 Jun; doi: 10.1016/j.urolonc.2019.05.018. Go to original source...
    33. Her HW, et al. Defining bacillus Calmette-Guerin refractory superficial bladder tumor. J Urol. 2003; 169: 1706. Go to original source... Go to PubMed...
    34. Zahoor H, Mir MC, Barata PC, Stephenson AJ, Garcia JA. Phase II trial of continuous treatment withi sunitinib in paients with high-risk (BCG-refractory) non-muscle invazive bladder cancer. Invest New Drugs. 2019 Jun;doi.org/10.1007/s10637-018-00716-w. Go to original source...
    35. Mangrud OM, et al. Reproducibility and prognostic value of WHO 1973 ond WHO 2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder. PloS One. 2014; 9: e83192. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.